Treatment of Tourette's syndrome with RO22-1319, a D-2-receptor antagonist.
D000293:Adolescent; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D008297:Male; D011954:Receptors, Dopamine / Q000187:drug effects*; D017448:Receptors, Dopamine D2; D005879:Tourette Syndrome / Q000188:drug therapy*
D014150:Antipsychotic Agents; D007546:Isoquinolines; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; C032412:Ro 22-1319